These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 14978191)

  • 21. Concentrations of mycophenolic acid and glucuronide metabolites under concomitant therapy with cyclosporine or tacrolimus.
    Patel CG; Harmon M; Gohh RY; Akhlaghi F
    Ther Drug Monit; 2007 Feb; 29(1):87-95. PubMed ID: 17304155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil.
    Jain AB; Hamad I; Zuckerman S; Zhang S; Warty VS; Fung JJ; Venkataramanan R
    Liver Transpl Surg; 1999 Mar; 5(2):101-6. PubMed ID: 10071348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients.
    Miura M; Kagaya H; Satoh S; Inoue K; Saito M; Habuchi T; Suzuki T
    Ther Drug Monit; 2008 Oct; 30(5):559-64. PubMed ID: 18695635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of metal cations on plasma trough concentration of mycophenolic Acid and its glucuronide in tacrolimus-treated and cyclosporine-treated kidney transplant recipients.
    Naito T; Mino Y; Otsuka A; Ushiyama T; Ozono S; Kagawa Y; Kawakami J
    Biol Pharm Bull; 2008 Jun; 31(6):1292-6. PubMed ID: 18520072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclosporine alters correlation between free and total mycophenolic acid in kidney transplant recipients in the initial phase.
    Mino Y; Naito T; Otsuka A; Takayama T; Ozono S; Kagawa Y; Kawakami J
    J Clin Pharm Ther; 2011 Apr; 36(2):217-24. PubMed ID: 21366651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation.
    Zucker K; Tsaroucha A; Olson L; Esquenazi V; Tzakis A; Miller J
    Ther Drug Monit; 1999 Feb; 21(1):35-43. PubMed ID: 10051052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Difference between pharmacokinetics of mycophenolic acid (MPA) in rats and that in humans is caused by different affinities of MRP2 to a glucuronized form.
    Takekuma Y; Kakiuchi H; Yamazaki K; Miyauchi S; Kikukawa T; Kamo N; Ganapathy V; Sugawara M
    J Pharm Pharm Sci; 2007; 10(1):71-85. PubMed ID: 17498396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gender-related differences in mycophenolate mofetil-induced gastrointestinal toxicity in rats.
    Stern ST; Tallman MN; Miles KK; Ritter JK; Dupuis RE; Smith PC
    Drug Metab Dispos; 2007 Mar; 35(3):449-54. PubMed ID: 17172313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.
    Cremers S; Schoemaker R; Scholten E; den Hartigh J; König-Quartel J; van Kan E; Paul L; de Fijter J
    Br J Clin Pharmacol; 2005 Sep; 60(3):249-56. PubMed ID: 16120063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice.
    Wang J; Figurski M; Shaw LM; Burckart GJ
    Transpl Immunol; 2008 Jul; 19(3-4):192-6. PubMed ID: 18586494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction and transport characteristics of mycophenolic acid and its glucuronide via human organic anion transporters hOAT1 and hOAT3.
    Uwai Y; Motohashi H; Tsuji Y; Ueo H; Katsura T; Inui K
    Biochem Pharmacol; 2007 Jun; 74(1):161-8. PubMed ID: 17462604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism-based enterohepatic circulation model of mycophenolic acid and its glucuronide metabolite: assessment of impact of cyclosporine dose in Asian renal transplant patients.
    Yau WP; Vathsala A; Lou HX; Zhou S; Chan E
    J Clin Pharmacol; 2009 Jun; 49(6):684-99. PubMed ID: 19386625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients.
    Naesens M; Kuypers DR; Streit F; Armstrong VW; Oellerich M; Verbeke K; Vanrenterghem Y
    Clin Pharmacol Ther; 2006 Nov; 80(5):509-21. PubMed ID: 17112807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mathematical modeling of the in vitro hepatic disposition of mycophenolic acid and its glucuronide in sandwich-cultured human hepatocytes.
    Matsunaga N; Wada S; Nakanishi T; Ikenaga M; Ogawa M; Tamai I
    Mol Pharm; 2014 Feb; 11(2):568-79. PubMed ID: 24320552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide.
    Naesens M; de Loor H; Vanrenterghem Y; Kuypers DR
    Transplantation; 2007 Aug; 84(3):362-73. PubMed ID: 17700162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacokinetics of mycophenolic acid in rats with orotic acid induced nonalcoholic fatty liver disease.
    Subali D; Kwon MH; Bang WS; Kang HE
    Can J Physiol Pharmacol; 2020 Mar; 98(3):169-176. PubMed ID: 31652406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation.
    Mino Y; Naito T; Matsushita T; Otsuka A; Ushiyama T; Ozono S; Hishida A; Kagawa Y; Kawakami J
    Ther Drug Monit; 2008 Dec; 30(6):656-61. PubMed ID: 18978521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable lung transplant recipients.
    Ting LS; Partovi N; Levy RD; Riggs KW; Ensom MH
    Ann Pharmacother; 2006 Sep; 40(9):1509-16. PubMed ID: 16882870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients.
    Djebli N; Picard N; Rérolle JP; Le Meur Y; Marquet P
    Pharmacogenet Genomics; 2007 May; 17(5):321-30. PubMed ID: 17429314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.